Plasma exchange
Conditions
Interventions
The treatment group:RCA combined with arginine hydrochloride in plasma exchange
The control group:RCA combined with placebo
Sponsors
The Medical Ethics Committee of the First Affiliated Hospital of the Air Force Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old; 2. Plasma was used as replacement fluid for plasma exchange therapy; 3. Plasma exchange was performed with RCA; 4. Willing to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe liver insufficiency (Child-Pugh score > 10 (chronic severe liver failure), MELD score > 30(acute severe liver failure), total bilirubin > 51 mu mol/L); 2. Shock with muscle hypoperfusion (serum lactic acid > 2mmol/L; Prolonged capillary refill time, skin spots or ecchymosis; Blood pressure 7.45, HCO3- > 27mmol/L); 5. The presence of infectious diseases such as hepatitis B, syphilis, HIV, etc.;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy end point of plasmapheresis: Successful completion of the treatment process;Acid-base disorders end point : Metabolic alkalosis/Severe alkalosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Anticoagulation-related complications;Adverse events of arginine hydrochloride drugs;Indicators of changes associated with the disease;Parameters of plasma exchange; | — |
Countries
China
Contacts
Public ContactMing Bai
The First Affiliated Hospital of the Air Force Medical University
Outcome results
None listed